Anavex Life Sciences Corp. (LON:0HFR)

Market Cap	561.87M
Revenue (ttm)	n/a
Net Income (ttm)	-37.14M
Shares Out	n/a
EPS (ttm)	-0.44
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,630
Average Volume	4,757
Open	8.74
Previous Close	8.81
Day's Range	8.50 - 8.86
52-Week Range	4.80 - 10.45
Beta	0.69
RSI	41.95
Earnings Date	Feb 5, 2025

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases in the United States. The company’s lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer’s disease and Parkinson’s disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. It also provides ANAVEX 3-71, wh...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2001
• Employees: 42
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0HFR

Financial Performance

Financial numbers in USD